Today’s New York Times has published another of its fantastic articles about cancer and coping with cancer. Today’s article, written by Jane Brody, discusses chemo brain. Until a short time ago, many doctors denied that it even existed, but today it is pretty much accepted as being real. One is said to suffer from chemo [...]
One of the first treatments used when diagnosed with advanced or recurrent prostate cancer is hormone therapy. Hormone therapy (androgen blockade) is a systematic treatment, or it treats the cancer through the entire body. Prostate cancer that is believed to be in the gland is treated with a localized, focused treatment of the actual gland [...]
Medivation, Inc. (MDVN) announced that its on-going clinical trial (phase I & II) of MDV3100 in castrate resistant prostate cancer has demonstrated both efficacy and safety in its current trials. The drug under study, MDV3100, is novel androgen receptor antagonist. This trial tracked 114 prostate cancer survivors who are hormone resistant (CRPC) for 12 weeks [...]
Combined androgen blockade with bicalutamide for advanced prostate cancer: Long-term follow-up of a phase 3, double-blind, randomized study for survival Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan has released some very significant survival data about a previously reported, double-blind, randomized, multicenter phase 3 trial. This trial compared combined androgen blockade [...]
The generic drug manufacturing company from India, Sun Pharmaceutical Industries Ltd, has received approval from the U.S. Food and Drug Administration (FDA) to sell a generic version of AstraZeneca's prostate cancer drug Casodex. Casodex (bicalutamide) is an anti-androgen that block the ability of androgens (testosterone) to access the prostate cancer cell and “fuel” them. Used [...]